New insights into tumor metabolism reveal promising pathways for cancer treatment
Peer-Reviewed Publication
Updates every hour. Last Updated: 23-Jun-2026 00:16 ET (23-Jun-2026 04:16 GMT/UTC)
A newly published review article highlights the critical role of fatty acid metabolism in shaping the tumor microenvironment and influencing cancer progression, offering fresh perspectives for the development of more effective therapies.
A new review article brings attention to the critical role of DNA methylation heterogeneity in shaping the tumor microenvironment, highlighting its growing importance in understanding cancer progression and advancing more precise treatment strategies.
A rapidly advancing area of biomedical innovation is shining a spotlight on miR-128-3p, a small yet powerful molecule with the potential to reshape how diseases—especially cancer—are detected, monitored, and treated. This microRNA, part of a broader class of non-coding RNAs, plays a critical role in regulating gene activity and maintaining cellular homeostasis.
Researchers at Toho University have uncovered a previously unrecognized mechanism controlling how dying cells release the inflammatory cytokine IL-33, a key driver of allergy, asthma, tissue inflammation, and cancer progression. The findings reveal that cells do not release IL-33 uniformly; instead, individual cells exhibit striking differences in release timing controlled by the membrane rupture protein NINJ1.
While many American adults are trying to reduce cholesterol levels, certain cancerous tumors have a relentless appetite for the metabolite. Some tumor cells use as much cholesterol as they can access to accelerate their growth beyond the capabilities of normal cells.
Scientists at Sanford Burnham Prebys Medical Discovery Institute and their collaborators at the University of Illinois Chicago have published findings May 22, 2026, in Science Advances regarding a potential method for turning the table on these tumors by subverting their cholesterol cravings.A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumour types.